Teva's Innovative Drug Portfolio Fuels Growth as Company Raises Outlook, Transitions to Direct NYSE Listing
Teva revenue tops estimates despite an earnings miss. The company raises 2026 sales guidance and highlights strong brand growth.
Teva sold more products than people expected, and the leaders say next year will be even better. When a company raises its outlook, that's a sign they feel confident about their business—worth watching to see if they deliver.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.